Astellas seeks new Xtandi indication

Share this article:

Astellas and Medivation have made pursuit of a pre-chemo indication for Xtandi official: the two companies announced Tuesday that they have filed a supplemental New Drug Application with the FDA so the oral drug can be used by metastatic castration-resistant prostate cancer patients earlier in treatment.

The drug is currently approved for patients who have already received docetaxel. The companies released the Phase-III data that is the basis of Tuesday's submission in January. The data indicated that an earlier intervention bought patients progression-free time.

Phase-III results also indicated that prostate-specific antigen levels fell by at least 50% among 75% of the test group, and overall survival was 29% greater with pre-chemo use compared to placebo.

Adding a pre-chemo indication to a post-chemo drug is not a new strategy: Roche moved its breast cancer drug Perjeta into first-line treatment for early stage breast cancer patients in September.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.